BioNTech Results Presentation Deck
Forward-looking statements
Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects, including the Company's views with respect to the potential for
mRNA therapeutics; the planned next steps in BioNTech's pipeline programs and specifically including, but not limited to, statements regarding plans to initiate clinical trials of
BioNTech's BNT111, BNT113, iNeST (BNT122), BNT 141, BNT142, BNT 151, BNT 152/153, BNT 161, BNT 162, BNT211 and BNT411; expectations for data announcements with respect
to BioNTech's BNT111, BNT114, iNeST (BNT 122), BNT131, BNT 162 and BNT311 clinical trials; the development of commercial capabilities and the transition of BioNTech to a fully
integrated biopharmaceutical company; its expectations with respect to interactions with regulatory authorities such as FDA and EMA, including the potential approval of BioNTech's or its
collaborators' current or future drug candidates; expected royalty and milestone payments in connection with BioNTech's collaborations; BioNTech's anticipated cash usage for fiscal year
2020; the creation of long-term value for BioNTech shareholders; and the ability of BioNTech to successfully develop and commercialize a vaccine for COVID-19 in partnership with Pfizer
and Fosun Pharma, constitute forward-looking statements, and the impact of COVID-19 on our clinical trials and business operations. Words such as "expects," "plans," "potential,"
"target," "continue" and variations of these words or similar expressions are intended to identify forward-looking statements. Such statements are based on the current beliefs and
assumptions of the management team of BioNTech and on the information currently available to the management team of BioNTech, and are subject to change. The Company will not
necessarily inform you of such changes. These forward looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause the
Company's actual results, performance or achievements to be materially different than any future results, performance or achievements expressed or implied by the forward-looking
statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the Company's ability to
discover and develop its novel product candidates, successfully demonstrate the efficacy and safety of its product candidates, the pre-clinical and clinical results for its product
candidates, which may not support further development of product candidates; actions of collaborators regarding continued product development and product commercialization; actions
of regulatory authorities, which may affect the initiation, timing and progress of clinical trials or the ability of the Company to obtain marketing authorization for its product candidates; the
Company's ability to obtain, maintain and protect intellectual property, the Company's ability to enforce its patents against infringers and defend its patent portfolio against challenges
from third parties; competition from others using technology similar to the Company's and others developing products for similar uses; the Company's ability to manage operating
expenses; the Company's ability to obtain additional funding to support its business activities and establish and maintain its existing and future collaborations and new business
initiatives; the Company's dependence on collaborators and other third parties for development, manufacture, marketing, sales and distribution of products; the outcome of litigation, and
unexpected expenditures. Any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent
date. The Company explicitly disclaims any obligation to update any forward-looking statements. The mRNA vaccines and other product candidates discussed in this slide presentation
are investigational products being developed by BioNTech and its collaborators and are not currently approved by the FDA, EMA or any other regulatory authority.
2
BIONTECHView entire presentation